The Proteomics Facility provides a comprehensive suite of proteomics services to the Cancer Center membership. The primary emphasis is to provide expert consultation and state-of-the-art technologies operating at maximum performance at affordable costs to Cancer Center members. This is quite challenging because unlike genomics, proteomics technologies are highly varied;there are not consensus optimal approaches for most problems, and instruments, software and analytical strategies continue to evolve rapidly. Therefore, equipment and analytical methods must be continually updated. As a result, most of the instruments in the Facility were purchased within the past grant period, which includes $1.3 million invested in 2008 alone to replace obsolete mass spectrometers with 2 LTQ Orbitrap mass spectrometers and a high sensitivity triple quadropole mass spectrometer. Sensitivity of protein identifications has increased more than 100-fold over the past grant period through a combination of method optimization, acquisition of more sensitive instruments and development of an improved data analysis pipeline. Other methods have been similarly improved and new complementary methods have been implemented. The facility is also beginning to implement quantitative protein profile comparisons on LC-MS/MS based analyses using several complementary approaches, which will be expanded during the next grant period. During the past grant period (2003-present), 19 CC members used the Proteomics Facility and additional members benefited because many projects were collaborative between multiple CC investigators. CC members receive priority in sample analysis, substantial discounts on user fees (35-50% depending upon the service), more extensive consultation, training and assistance, and early access to methods/technologies not yet implemented as routine services. In the current year CCSG support covered 27% of non-equipment operating costs and will cover 23% of operating costs during the first year of the proposed grant. During 2007 44% of facility usage was by peer-reviewed CC members, and over the entire past grant period (2003-present) 61% of facility usage was by peer-reviewed CC members.

Public Health Relevance

Proteomics can only be accomplished as a facility because of the expense of the instrumentation and expertise needed for their operation. Proteomics offer the hope of identifying biomarkers for the early detection of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8932923
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$187,370
Indirect Cost
$84,168
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Seo, Jae Ho; Rivadeneira, Dayana B; Caino, M Cecilia et al. (2016) The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biol 14:e1002507
Haut, Larissa H; Gill, Amanda L; Kurupati, Raj K et al. (2016) A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods :
Peck, Barrie; Schug, Zachary T; Zhang, Qifeng et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6
Tempera, Italo; De Leo, Alessandra; Kossenkov, Andrew V et al. (2016) Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol 90:345-55
Nelson, David M; Jaber-Hijazi, Farah; Cole, John J et al. (2016) Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol 17:158
Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii et al. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37:208-20
Kung, Che-Pei; Murphy, Maureen E (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61-R75
Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31
Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72
Vazquez, Alexei; Kamphorst, Jurre J; Markert, Elke K et al. (2016) Cancer metabolism at a glance. J Cell Sci 129:3367-73

Showing the most recent 10 out of 582 publications